Mutual of America Capital Management 13F: Adds $2M to KRYS Stake

Mutual of America Capital Management increased its position in Krystal Biotech, Inc. KRYS by 19.2%, acquiring 6,149 shares during the quarter, according to a Form 13F filing with the SEC on October 23, 2026. The purchase brought the firm's total ownership to 38,147 shares valued at about $12.7 million.

KRYS Krystal Biotech, Inc.

$311.50 ▲ +26.16% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mutual of America Capital Management's Krystal Biotech, Inc. Position

The institutional investor grew its stake from 31,998 shares up to 38,147 shares. This 19.2% increase reflects a larger commitment to the biotechnology developer during the period.

Other Institutional Activity in Krystal Biotech, Inc.

Avoro Capital Advisors LLC kept its holdings steady at 2,888,888 shares worth about $899.9 million. Meanwhile, Soleus Capital Management, L.P. trimmed its position by 213,771 shares, dropping its holdings 18.5% down to 939,254 shares valued at roughly $292.6 million.

Krystal Biotech, Inc. Stock Down 3.3%

The shares recently traded around $311.50 as of October 24, 2026, sitting right around the same level as the $311.50 close on the filing date. The stock trades above its 200-day moving average of $306.97 while remaining below its 52-week high of $382.54.

Recent Earnings

Krystal Biotech, Inc. generated $440.48 million in trailing twelve month revenue with a net profit margin of 54.8%. The company reported basic earnings of $7.98 per share and a return on equity of 20.1%. Its next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Krystal Biotech, Inc.

General Counsel John Charles Michael Thomas sold 1,000 shares on June 25, 2026, at a price of $347.27 for a total of $347,270. Director Dino A Rossi sold 25,000 shares on August 14, 2026, worth $8,227,953. Officer and Director Suma M Krishnan sold 25,000 shares on September 4, 2026, valued at $8,982,986. Finally, Chief Executive Officer Krish S Krishnan sold 25,000 shares on September 4, 2026, for a total value of $8,983,084.

Analysts Set New Price Targets

B of A Securities maintained a Buy rating on July 14, 2026, lifting its target from $364.00 to $396.00. Citigroup maintained a Buy rating on August 4, 2026, raising its target to $386.00 from $378.00. RBC Capital initiated coverage with an Outperform rating and a $400.00 target on August 14, 2026. B of A Securities again maintained a Buy rating on September 21, 2026, moving its target up to $400.00 from $392.00. HC Wainwright & Co. reiterated a Buy rating with a $361.00 target on October 15, 2026. The stock currently holds a consensus Strong Buy rating across nine analyst opinions with a mean target of $395.44.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology business based in Pittsburgh, Pennsylvania. The company focuses on discovering, manufacturing, and commercializing genetic medicines for severe conditions, notably marketing VYJUVEK for the treatment of dystrophic epidermolysis bullosa.

Bottom Line

Investors will watch for the company's upcoming earnings release on November 2, 2026, to gauge ongoing revenue growth. Institutional filings and analyst updates continue to draw attention to the healthcare firm's market trajectory.